Antibody response to SARS‐CoV‐2 in infected patients with different clinical outcome
Open Access
- 11 January 2021
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (4), 2548-2552
- https://doi.org/10.1002/jmv.26789
Abstract
Data regarding antibody responses to SARS‐CoV‐2 in patients infected with COVID‐19 are not yet available. In this study, we aimed to evaluate serum antibody responses in patients regardless of the outcome. We measured the circulating IgG antibody levels in 60 subjects with a certified history of SARS‐CoV‐2 infection by using immunoenzymatic, chemiluminescent, and Neutralization assays. Half patients had a severe infection, the other half were pauci‐symptomatic. We analyzed their antibody response to see the trend of the humoral response. Our results showed a significant difference in circulating IgG level among the two groups. The neutralizing antibody response against SARS‐CoV‐2 was significantly higher among those who had severe disease. Furthermore, ten subjects from each group were screened twice, and a declining antibody trend was observed in pauci‐symptomatic individuals. These findings provide evidence that humoral immunity against SARS‐CoV‐2 in pauci‐symptomatic people is weak and may not be long‐lasting. This may have implications for immunity strategy and prevention, since it is still not clear whether a time‐dependent decrease of both circulating and neutralizing antibodies to non‐protective levels could occur in a longer time span and whether potential vaccines are able to induce a herd immunity and a durable response.This publication has 19 references indexed in Scilit:
- Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)Science, 2020
- Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS–CoV-2/COVID-19mBio, 2020
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoVNature Communications, 2020
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)Clinical Infectious Diseases, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Transmission dynamics and evolutionary history of 2019‐nCoVJournal of Medical Virology, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracleJournal of Medical Virology, 2020
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryThe New England Journal of Medicine, 2007
- Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibody in SARS PatientsClinical and Vaccine Immunology, 2005